Pelthos Therapeutics Inc. Deferred Tax Assets, Capital Loss Carryforwards
Pelthos Therapeutics Inc. (PTHS) had Deferred Tax Assets, Capital Loss Carryforwards of $4.30 million as of 2024-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsCapitalLossCarryforwards · last filed 2025-03-27
- 2024-12-31: Deferred Tax Assets, Capital Loss Carryforwards $4.30M.
- 2023-12-31: Deferred Tax Assets, Capital Loss Carryforwards $2.25M.
- 2022-12-31: Deferred Tax Assets, Capital Loss Carryforwards $1.76M.
| Period end | Deferred Tax Assets, Capital Loss Carryforwards |
|---|---|
| 2024-12-31 | $4.30M 10-K · filed 2025-03-27 |
| 2023-12-31 | $2.25M 10-K · filed 2025-03-27 |
| 2022-12-31 | $1.76M 10-K · filed 2024-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |